HongKong Nasopharyngeal

Information about HongKong Nasopharyngeal

Published on January 21, 2008

Author: Monica

Source: authorstream.com

Content

Slide1:  For demonstration of interpreting a strong positive interaction see slides 25-30. NPC-9902 Trial on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Cancer:  NPC-9902 Trial on Therapeutic Gain by Concurrent Chemotherapy and/or Accelerated Fractionation for Locally-Advanced Nasopharyngeal Cancer Anne W. M. Lee for Hong Kong Nasopharyngeal Cancer Study Group Estimation on Sample & Eligible Patients:  Estimation on Sample & Eligible Patients Incidence in Hong Kong: CT-staged patients NPC-9902: Eligibility Criteria:  NPC-9902: Eligibility Criteria Non-keratinizing / Undifferentiated type T3-4 N0-1 M0 (UICC 5th) Staging Ix: CT / MR X-ray / CT thorax + metastatic work-up Eligibility Criteria :  Eligibility Criteria Slide6:  CF CF+C Stratification by center, N-stage, T-stage Randomization (equal proportion) AF AF+C CF = conventional fractionation; AF = accelerated fractionation; +C = plus chemotherapy RT: Same for all Arms:  RT: Same for all Arms RT: Fractionation:  RT: Fractionation Fractionation dose: 2 Gy/ Fr Treatment in CRT Arm:  Treatment in CRT Arm Chemotherapy (IGS regimen)   Concurrent Adjuvant P 80 + 5FU 1000 x 4d (q4 wk x 3 cycles) Statistical Consideration:  Statistical Consideration Target accrual = 464 patients Hypothesis Improve Failure-Free Survival (FFS) [Time to failure (any site)] from 45% to 55% (5-year) (alpha = 0.05, power = 90%) Other End Points:  Other End Points Progression-Free Survival (PFS) [Time to first failure or death (any cause)] Overall Survival Participating Centers:  Participating Centers Accrual Rate:  Accrual Rate July 1999 – April 2004: 189 patients Slide14:  Premature Termination due to Slow Accrual Recommendation by Data Monitoring Committee Results:  Results Period: Jul 1999 – Apr 2004 Total No. randomized: 189 pt. Regular follow-up: 97% Median follow-up: 2.9 (0.1 – 5.5) yr Patient Characteristics:  Patient Characteristics Tumor Staging:  Tumor Staging Radiotherapy:  Radiotherapy Comparison of Prognostic Factors:  Comparison of Prognostic Factors RT vs CRT All balanced CF vs AF All balanced Arm Balanced except AF Arm vs other Arms: Male: 90% vs 70% (p = 0.046) PS 2: 4% vs 0% Non-Chinese: 4% vs 0% Major Violation of Protocol:  Major Violation of Protocol Compliance to Chemotherapy:  Compliance to Chemotherapy AF+C 84% 73% Concurrent cycles: > 2 Adjuvant cycles: > 3 CF+C 92% 64% Acute Toxicity (Grade >3):  Acute Toxicity (Grade >3) Chemotherapy Toxicity in CRT Arm:  Chemotherapy Toxicity in CRT Arm Overall Acute Toxicity (Grade >3):  Overall Acute Toxicity (Grade >3) Overall Acute Toxicity (Grade >3):  Overall Acute Toxicity (Grade >3) Failure-Free Survival (3-year):  Failure-Free Survival (3-year) RT vs CRT 66% vs 83% (p = 0.05) AF vs AF 72% vs 77% (p = 0. 31) (Event: any failure) AF+C CF AF AF+C Year Probability P=0.01 Failure-Free Survival (3-year):  Failure-Free Survival (3-year) CF This represents a significant interaction effect. What does it mean? Effects of CRT and AF are non-additive: Effect of CRT is enhanced in presence of AF and Effect of AF is enhanced in presence of CRT. Is it real? Is CRT useless without AF? Is AF useless without CRT? Slide28:  Hazard Ratio = .11 = 1/9  Nine-fold decrease in failure with AF + CRT together rather than separately. But the decrease is a product of three effects: RT + AF CRT + CF RT + CF ------------------------------------------------ CRT + AF CRT alone, HR  1.1 AF alone, HR  1.4 CRT + AF, HR  6 1.1  1.4  6 = 9, the total effect Slide29:  That is, the benefit due to CRT + AF being delivered in tandem vs. separately is due to: The apparent disadvantage of CRT + CF over RT + CF (1.1 increase); The apparent disadvantage of RT + AF over RT + CF (1.4 increase); and The advantage of CRT + AF over RT + CF (six-fold reduction): 1.1  1.4  6 = 9, the total interaction effect. A clinically important question::  A clinically important question: Suppose we don’t believe the first two effects – we don’t believe that acceleration or adding chemotherapy can cause failures, and fix their hazard ratios at 1.0: What is the significance of the “restricted interaction effect”, the hazard ratio of 6? Answer: p = ????. Modest evidence that AF and CRT do seem to work better together. Locoregional Failure-Free Rate (3-year):  Locoregional Failure-Free Rate (3-year) RT vs CRT 81% vs 87% (p = 0.41) AF vs AF 83% vs 85% (p = 0. 63) Probability Year P=0.14 AF+C CF CF+C AF Distant Failure-Free Rate (3-year):  Distant Failure-Free Rate (3-year) RT vs CRT 79% vs 93% (p = 0.06) AF vs AF 85% vs 86% (p = 0. 55) Year Probability AF+C CF CF+C AF P=0.10 Disease Status at Last Assessment:  CF+C 69 6 8 12 2 2 2 CF 71 5 7 14 - - 2 Disease Status at Last Assessment AF 67 6 4 19 - 2 2 AF+C 89 - - 5 - 7 - Overall Survival :  Overall Survival RT vs CRT 77% vs 87% (p = 0.41) AF vs AF 85% vs 79% (p = 0.73) Year Probability AF+C CF AF CF+C P=0.56 Progression-Free Survival :  Progression-Free Survival (Event: failure or death) RT vs CRT 65% vs 80% (p = 0.19) AF vs AF 71% vs 74% (p = 0.34) Year Probability AF+C CF+C CF AF P=0.09 Late Toxicity (Grade >3):  Late Toxicity (Grade >3) RT vs CRT 19% vs 33% (p = 0.08) AF vs AF 23% vs 28% (p = 0.32) Year Probability AF+C CF+C AF CF P=0.24 Late Toxicity (Grade >3):  Late Toxicity (Grade >3) Subset Analyses – Absolute Gain:  Subset Analyses – Absolute Gain

Related presentations


Other presentations created by Monica

PORT WINE presentation
22. 01. 2008
0 views

PORT WINE presentation

Earth Science Life on Mars
25. 01. 2008
0 views

Earth Science Life on Mars

cyberbullying 11 16 07web
30. 01. 2008
0 views

cyberbullying 11 16 07web

pmi quality notes
09. 01. 2008
0 views

pmi quality notes

Metamorphism 1
10. 01. 2008
0 views

Metamorphism 1

Cavemen
10. 01. 2008
0 views

Cavemen

Helen Chiu NZ 2001
14. 01. 2008
0 views

Helen Chiu NZ 2001

Meeting 21 5 2007 DEI
16. 01. 2008
0 views

Meeting 21 5 2007 DEI

0105
21. 01. 2008
0 views

0105

DWARKA Krishnas city
22. 01. 2008
0 views

DWARKA Krishnas city

Lesson11
22. 01. 2008
0 views

Lesson11

PLE01 Show
22. 01. 2008
0 views

PLE01 Show

MacMillan Matrix
04. 02. 2008
0 views

MacMillan Matrix

abridged
10. 01. 2008
0 views

abridged

Class2
09. 01. 2008
0 views

Class2

06Firstladyintimacy
17. 01. 2008
0 views

06Firstladyintimacy

20070513a commitment in marriage
29. 01. 2008
0 views

20070513a commitment in marriage

A3 2 Cihangir
07. 02. 2008
0 views

A3 2 Cihangir

Slag Proj sum jmv
14. 02. 2008
0 views

Slag Proj sum jmv

Catalog Powerpoint
26. 02. 2008
0 views

Catalog Powerpoint

200632165149775
28. 02. 2008
0 views

200632165149775

WirelessChannels
24. 03. 2008
0 views

WirelessChannels

TecEcoKyotoOpportuni ties090605
12. 02. 2008
0 views

TecEcoKyotoOpportuni ties090605

PACIFICO1
28. 03. 2008
0 views

PACIFICO1

Cow Calf Assessment Data All
24. 01. 2008
0 views

Cow Calf Assessment Data All

553147
14. 04. 2008
0 views

553147

FINALSUSAppt
15. 04. 2008
0 views

FINALSUSAppt

scoresslam with poems
12. 02. 2008
0 views

scoresslam with poems

200832519533687
17. 04. 2008
0 views

200832519533687

waters fiona
22. 04. 2008
0 views

waters fiona

Part 1 Topic 3 LUBS1940
23. 04. 2008
0 views

Part 1 Topic 3 LUBS1940

get big fast lecture1
24. 04. 2008
0 views

get big fast lecture1

AIDS and Access A Summary
07. 05. 2008
0 views

AIDS and Access A Summary

pl311wittgensteinnot heory06 07
02. 05. 2008
0 views

pl311wittgensteinnot heory06 07

Thompson ACE dept sem 012607
23. 01. 2008
0 views

Thompson ACE dept sem 012607

PE2 U9 R
19. 03. 2008
0 views

PE2 U9 R

1877
11. 01. 2008
0 views

1877

visite multilingue
10. 01. 2008
0 views

visite multilingue

2 3pc
25. 01. 2008
0 views

2 3pc

2007 10 21 for website
05. 02. 2008
0 views

2007 10 21 for website

Dichronic Jewerly
09. 01. 2008
0 views

Dichronic Jewerly

fischer cap2007
16. 01. 2008
0 views

fischer cap2007

3p21
14. 01. 2008
0 views

3p21

katysat adcs update 2006 01 31
17. 01. 2008
0 views

katysat adcs update 2006 01 31